Concepedia

Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

Connie Cheng, Daniel Woronow, Afrouz Nayernama, Tanya Wroblewski, S. Christopher Jones

Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 25 citations · 6 references

DOI

Concepts

Abstract

"Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System." Leukemia & Lymphoma, 59(12), pp. 3016–3017

References

6

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

Douglas P. Zipes, A. John Camm, Martin Borggrefe et al. · Journal of the American College of Cardiology · 2006 · 2K citations

, , +15

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Oliver Hantschel, Uwe Rix, Uwe Schmidt et al. · Proceedings of the National Academy of Sciences · 2007 · 282 citations · Full text

, , +16

Ventricular Tachycardia and Sudden Cardiac Death

Bruce A. Koplan, William G. Stevenson · Mayo Clinic Proceedings · 2009 · 207 citations

, , +12

Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia

János Tomcsányi, Zoltán Nényei, Zoltán Mátrai et al. · JACC. Clinical electrophysiology · 2016 · 35 citations

, , +16

A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma

Natalie Wallace, Ellice Wong, Dennis Cooper et al. · Clinical Case Reports · 2016 · 28 citations · Full text

, , +17